Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Abstract Background Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease. Methods Direct and indirect costs (based on self-reported information on healthcare utilization) and health-related quality of life (HRQL, as assessed by SGRQ, CAT, and EQ-5D-3 L) were compared b...

Full description

Bibliographic Details
Main Authors: Florian M. Karl, Rolf Holle, Robert Bals, Timm Greulich, Rudolf A. Jörres, Annika Karch, Armin Koch, Stefan Karrasch, Reiner Leidl, Holger Schulz, Claus Vogelmeier, Margarethe E. Wacker, for the COSYCONET Study Group
Format: Article
Language:English
Published: BioMed Central 2017-04-01
Series:Respiratory Research
Subjects:
COPD
Alpha-1-Antitrypsin Deficiency
Direct costs
Indirect costs
Health-related quality of life
Augmentation therapy
Online Access:http://link.springer.com/article/10.1186/s12931-017-0543-8

Similar Items

Similar Items